skip to main
|
skip to sidebar
KinasePro
Daily news on kinase inhibitors.
Sunday, August 31, 2008
JAK2 - University of Florida
Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth.
Sayyah J, Magis A, Ostrov DA, Allan RW, Braylan RC, Sayeski PP.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
Labels
550
(1)
Abbott
(1)
Akt
(1)
Amgen
(1)
Angiokinase
(1)
Astellas
(1)
Aurora2
(1)
Axitinib
(1)
B-Raf
(2)
BMS
(2)
Boehringer Ingelheim
(1)
C-MET
(2)
CAMK2A
(1)
CDK
(1)
CEP-1347
(1)
Cephalon
(2)
CK1e
(1)
Clinical Trial
(10)
Computational
(4)
CP-690
(1)
Dasatinib
(1)
Eberhard-Karls-University Tuebingen
(1)
EGFR
(1)
Genentech
(1)
GSK
(2)
GSK3
(1)
IGF-1R
(1)
IRAK4
(1)
JAK2
(1)
JNK
(1)
Lapatinib
(1)
Lck
(1)
Motesanib
(1)
mTOR
(1)
Nilotinib
(1)
p38
(2)
PDB
(3)
PDK1
(1)
Pfizer
(3)
Phase II
(1)
PI3K
(2)
Pim1
(1)
Piramed
(1)
PKA
(1)
PLK
(1)
Plk1
(1)
Riboxistaurin
(1)
Sorafenib
(1)
Src
(1)
Sunitinib
(1)
Tie1
(1)
TrkA
(1)
UCB
(1)
University of Florida
(1)
University of Kentucky
(1)
University of Pittsburgh
(1)
University of Rhode Island
(1)
Blog Archive
►
2009
(1)
►
07/05 - 07/12
(1)
▼
2008
(32)
►
09/07 - 09/14
(3)
▼
08/31 - 09/07
(10)
Patent Publications - 09/04/2008
PKA/Akt - Abbott
p38 - BMS
IRAK4 - UCB
TrkA - Cephalon
Src - University of Rhode Island
p38 - Eberhard-Karls-University Tuebingen
JAK2 - University of Florida
JNK - Pfizer
PI3K - Piramed/Genentech
►
08/24 - 08/31
(11)
►
08/17 - 08/24
(8)
On the Market
Dasatinib
Erlotinib
Gefitinib
Imatinib
Lapatinib
Nilotinib
Temsirolimus
No comments:
Post a Comment